No Data
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
Cadrenal Therapeutics Files to Sell 590K Shares of Common Stock for Holders
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Cadrenal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Cuts Target Price to $32
Express News | Cadrenal Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $32 From $3 to Reflect 1-for-15 Reverse Stock Split
No Data
No Data
